AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view
AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.